We report that in 45 metastatic CRC patients treated with anti-EGFR agents and with wild-type KRAS and BRAF gene status, those expressing diffuse TOPK staining suffer from a significant adverse prognosis. This evidence concerns the gene KRAS and colorectal carcinoma.